What is it about?
We found that CRIPTO protein presence in hepatocellular carcinoma makes this cancer more aggressive. Also that when this cancer is treated with Sorafinib, inhibition of CRIPTO makes the treatment more effective.
Featured Image
Why is it important?
We have used patient derived needle biopsies, generate patent derived xenograft and organoids and shown that the combination treatment is effective in both models.
Read the Original
This page is a summary of: CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma, The Journal of Pathology, May 2018, Wiley,
DOI: 10.1002/path.5083.
You can read the full text:
Contributors
The following have contributed to this page
